Singapore markets closed

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.16-0.27 (-3.20%)
At close: 04:00PM EDT
8.19 +0.03 (+0.37%)
After hours: 07:52PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close8.43
Bid8.14 x 1500
Ask8.17 x 3000
Day's range8.06 - 8.40
52-week range3.21 - 18.33
Avg. volume5,714,525
Market cap2.283B
Beta (5Y monthly)0.80
PE ratio (TTM)N/A
EPS (TTM)-1.81
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est25.92
  • Simply Wall St.

    Exploring Three US Growth Companies With Substantial Insider Ownership

    Amidst a backdrop of fluctuating markets and evolving economic indicators, the U.S. stock market has shown resilience in various sectors despite recent downturns in tech giants. As investors navigate through these uncertain times, understanding the role of insider ownership in growth companies becomes increasingly relevant. In this environment, companies with substantial insider ownership can be appealing as they often indicate a leadership team deeply invested in the company's long-term...

  • GlobeNewswire

    Iovance Biotherapeutics to Present at Upcoming Conferences and Events

    SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHAFireside Chat: May 28, 2024 at 3:00 p.m. ETVirtual Iovance ASCO Invest

  • Zacks

    Iovance (IOVA) Up 5% on Updated Data From Melanoma Study

    Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.